Physician profile
Philip Konits
NPI 1700852159
$1,948.08
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $221 · 2021: $229 · 2022: $444 · 2023: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $294.97 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $262.96 | 2019-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $240.63 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $182.28 | 2021-2023 | Jaypirca, Retevmo, Verzenio |
| Eisai INC. | $137.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $99.73 | 2019-2021 | |
| Amgen INC. | $82.93 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $76.15 | 2019-2022 | |
| Celgene Corporation | $75.94 | 2022-2023 | Pomalyst, Opdualag |
| Genzyme Corporation | $72.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.33 | 2021-2023 | Calquence, Imfinzi |
| Daiichi Sankyo INC. | $55.91 | 2022 | |
| Janssen Biotech, INC. | $44.75 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.67 | 2021-2022 | |
| Taiho Oncology, INC. | $37.54 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.32 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $26.31 | 2023 | Tazverik |
| Abbvie INC. | $25.14 | 2019 | |
| Astellas Pharma US INC | $18.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.16 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.78 | 2022 | |
| Verastem, INC. | $13.81 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $12.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Konits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.